Investment Rating - The investment rating for the company is "Buy" with a target price not specified [5] Core Views - The company has shown strong performance in its financial results, with a 2024 revenue of 10.778 billion yuan, representing a year-on-year increase of 21.04%, and a net profit of 1.552 billion yuan, up 30.00% year-on-year [1] - The gross margin has improved, reaching 71.39% in 2024, an increase of 1.46 percentage points year-on-year, and the net profit margin increased to 14.40%, up 0.99 percentage points year-on-year [2] - The main brand continues to innovate with new product launches, contributing to a revenue of 8.581 billion yuan in 2024, a 19.55% increase year-on-year [3] Financial Performance Summary - 2024 revenue: 10.778 billion yuan, up 21.04% year-on-year [1] - 2024 net profit: 1.552 billion yuan, up 30.00% year-on-year [1] - 2025 Q1 revenue: 2.359 billion yuan, up 8.13% year-on-year [1] - 2024 gross margin: 71.39%, up 1.46 percentage points year-on-year [2] - 2024 net profit margin: 14.40%, up 0.99 percentage points year-on-year [2] Product Development and Market Position - The main brand has launched several new products, including the upgraded Ruby and Energy series, enhancing its anti-aging product matrix [3] - The small brand OR has shown remarkable growth with a revenue increase of 71.14% year-on-year, reaching 368 million yuan [3] - The company is expected to maintain its growth trend and increase market share through a solid product strategy [4] Financial Forecast - Expected revenue for 2025-2027: 12.466 billion yuan, 14.159 billion yuan, and 15.953 billion yuan respectively [4] - Expected net profit for 2025-2027: 1.807 billion yuan, 2.095 billion yuan, and 2.402 billion yuan respectively [4] - Corresponding P/E ratios for 2025-2027 are projected at 19x, 16x, and 14x respectively [4]
珀莱雅(603605):25年一季报业绩变现亮眼,盈利能力持续提升